Ms. Stoltenberg earned an MBA, Beta Gamma Sigma, at Columbia Business School and bachelor’s degrees in electrical engineering and management at Bucknell University.About Exact Sciences Corp. Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com. Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this presentation may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results of our pivotal clinical trial, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports of Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Exact Sciences Corp. (Nasdaq: EXAS), a molecular diagnostics company focused on colorectal cancer, today announced the appointment of Laura S. Stoltenberg as chief commercial officer. In this role, she will be responsible for developing and executing Exact's global commercial strategies and join the company’s executive management team. Ms. Stoltenberg brings nearly two decades of experience in sales, marketing, business development and general management to her role at Exact. She was most recently vice president and general manager of GE Healthcare Lunar, a global leader in bone densitometry and body composition instruments. While at Lunar, Ms. Stoltenberg expanded the business’s market leadership, increased its international presence, improved operating profitability and oversaw the launch of several new products, including a revolutionary body composition test used in the assessment of cardio-metabolic risk. “We are pleased to welcome Laura to Exact’s management team,” said Kevin T. Conroy, Exact’s president and chief executive. “Laura’s broad range of leadership experiences in strategic marketing, business development and international business are a great fit for Exact and will help us capture the significant opportunities we’ve identified. She will be a key leader in the company’s execution on our priorities as we move towards the completion of our clinical trial, FDA submission and beyond.” “I am excited to join the team at Exact, as we work to bring the Cologuard test to market,” Ms. Stoltenberg said. “The chance to positively affect the outcomes of tens of thousands of colorectal cancer patients is very real. I look forward to working with Exact’s talented team to provide Cologuard to patients and physicians worldwide.” Before being appointed Lunar’s general manager in 2007, Ms. Stoltenberg served as director of business development at GE Healthcare, where she led strategy development and acquisition activities for four of its business units, including medical diagnostics. Ms. Stoltenberg also served as manager, business development at GE Healthcare’s IT business unit and in several commercial positions at GE Industrial Systems.